SeptiCyte® RAPID

Key Features:

• Rapid, one-hour sepsis diagnosis

• Utilizes host gene expression biomarkers (PLA2G7 and PLAC8)

• Operates on the Biocartis Idylla™ platform

• Fully automated, sample-to-answer system

Intended Use:

Aids in differentiating infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis upon ICU admission.

Certifications:

• FDA 510(k) Cleared

• CE-IVD Marked for European use

Availability:

• Available for immediate deployment